^
Association details:
| Biomarker: | MET amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tabrecta (capmatinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
Excerpt:
...- cMET amplification by FISH (GCN ≥ 6),...
Source:
Title:
Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC
Excerpt:
...- Participant must have either MET exon 14 mutations and/or high level MET amplification...
Trial ID:
More C2 evidence
Source:
Title:
Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy
Excerpt:
...- Histologically or cytologically confirmed diagnosis of NSCLC with EGFR mutations known to be associated with EGFR TKI sensitivity, EGFR T790M negative and MET gene amplification...
Trial ID:
Source:
Title:
Study of safety and efficacy of capmatinib in combination with osimertinib compared to platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR activating mutations and T790M negative who have progressed on prior EGFR-TKI therapy Estudio de la seguridad y la eficacia de capmatinib en combinación con osimertinib, comparado con quimioterapia basada en doblete de platino y pemetrexed, en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico con mutaciones activadoras del EGFR y mutación T790M negativa que hayan progresado a un tratamiento previo con TKI del EGFR u osimertinib.
Excerpt:
...Histologically or cytologically confirmed diagnosis of NSCLC with EGFR mutations known to be associated with EGFR TKI sensitivity, T790M negative, and MET gene amplification defined as Gene Copy Number (GCN) > or = 5 per central Novartis laboratory 5. ...
Trial ID:
Source:
Title:
Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations
Excerpt:
...Positive for MET amplification or METΔex14 mutation using Predicine's cfDNA assay (PredicineCARE)....
Trial ID:
Less C2 evidence
Source:
Title:
Capmatinib response in patients with advanced non–small cell lung cancer (NSCLC) harboring focal MET amplifications: Analysis from the phase 2, multicohort GEOMETRY mono-1 study
Published date:
10/12/2022
Excerpt:
Of all pts with focal METamp, most were in high MET-amplified C1a (14 of 18 pts [78%]). In C1a, the distribution of GCN by FISH was similar in pts with focal vs nonfocal METamp but more responders were found in pts with focal vs nonfocal METamp (ORR, 57% vs 13%). In C1b, 3 of 32 pts (9%) had focal METamp; 2 were responders...For pts with high MET-amplified NSCLC by FISH, a numerically higher proportion of responders to capmatinib was observed in pts with focal vs nonfocal METamp.
Source:
Title:
MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review
Published date:
03/10/2022
Excerpt:
The GEOMETRY mono-1 study evaluated the efficacy and safety of capmatinib in patients with high-level MET-amplified advanced NSCLC (GCN ≥ 10) compared with low-level (GCN < 4) or midlevel (GCN 4–5 or 6–9) MET-amplified advanced NSCLC. In this study, patients with GCN ≥ 10 and no prior line of therapy exhibited higher ORRs (40%) and PFS (4.2 months) than other cohorts, indicating a better response with higher MET amplification.
DOI:
10.1007/s40291-021-00568-w
Source:
Title:
A Phase II Study of Capmatinib in Patients with MET-Altered Lung Cancer Previously Treated with a MET Inhibitor
Published date:
02/02/2021
Excerpt:
Patients with advanced NSCLC harboring MET amplification or MET exon 14 skipping received capmatinib 400 mg twice daily...Overall, the median PFS and OS were 5.5 (95% CI 1.3-11.0) and 11.3 (95% CI 5.5-not reached) months
DOI:
10.1016/j.jtho.2021.01.1605
Source:
Title:
The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification
Published date:
01/29/2021
Excerpt:
A total of 72 patients were included in this analysis (Group A: GCN ≥ 10 or METex14, n=14; Group B: others, n=58)….within Group A, median OS was 21.5 months (95% CI, 20.8 - NA) for capmatinib-treated, and 7.5 months (95% CI, 3.2 - NA) for capmatinib-untreated patients (p=0.025).
DOI:
10.4143/crt.2020.1331
Source:
Title:
Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study
Published date:
01/28/2021
Excerpt:
In MET-amplified patients with a MET gene copy number of ≥10, the ORR was 100% (2/2 patients) in the 1L group and 45.5% (5/11 patients) in the 2/3L group, with DOR of 8.2 and 8.3 months, respectively.
DOI:
10.1111/cas.14826
Trial ID:
Source:
Title:
Capmatinib in patients with high-level MET-amplified advanced non–small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study.
Published date:
05/13/2020
Excerpt:
Per BIRC assessment in cohorts 1a and 5a, respectively, ORR was 29% and 40%, median DOR was 8.31 months (mo, 20 responders, 95% CI: 4.17–15.44) and 7.54 mo (6 responders, 95% CI: 2.56–14.26), and median PFS was 4.07 (95% CI: 2.86–4.83) and 4.17 (95% CI: 1.45–6.87) mo....Capmatinib has demonstrated activity in the subset of pts with high-level MET-amplified (GCN≥10) NSCLC, with a higher response rate in tx-naïve pts.
DOI:
10.1200/JCO.2020.38.15_suppl.9509
Trial ID:
Source:
Title:
MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
Published date:
11/15/2023
Excerpt:
In vitro clonogenic survival assays demonstrated radiosensitization with capmatinib in both MET exon 14-mutated and MET-amplified NSCLC cell lines.
DOI:
https://doi.org/10.1016/j.ijrobp.2023.11.013
Source:
Title:
EP08.02-135 - Anti-EGF Antibodies Significantly Improve the Activity of MET and KRAS Inhibitors in Preclinical Models of Non-small Cell Lung Cancer (NSCLC)
Published date:
07/12/2022
Excerpt:
...we tested if anti-EGF VacAbs could improve the antitumor activity of capmatinib, tepotinib and sotorasib in MET amplified, MET Δ14 and KRAS mutant non-small cell lung cancer (NSCLC) cell lines....In combination, anti-EGF VacAbs significantly enhanced the antitumor activity of capmatinib and tepotinib in EBC1 (MET-amplified) and Hs746T (METΔ14), potentiating the blockade of EGFR, Akt and Erk 1/2 phosphorylation. The same effects were observed when combining anti-EGF VacAbs with sotorasib in H2122 and H23 (G12C) cells.
Secondary therapy:
EGF inhibitor
